EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study

Ali Aytac, Berkay Mehmet Ozata, Ibrahim Halil Erdogdu, Ali Alkan, Ozgur Tanriverdi

Virchows Archiv · 2026-07 · 489 (1) · 79-90

DOI: 10.1007/s00428-026-04559-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Virchows Archiv, online erschienen am 04.05.2026. Verfasst von Ali Aytac und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Türkiye. Hauptthemen laut MEDLINE: Mutation, Lung Neoplasms, Adenocarcinoma of Lung, Rapamycin-Insensitive Companion of mTOR Protein. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mugla Sitki KocmanUniversity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RICTOR, a scaffold protein of the mTORC2 complex, regulates AKT signaling and has been implicated in tumor progression and therapy resistance across multiple cancers. However, the prognostic impact of RICTOR mutations in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma remains unclear. This study aimed to evaluate the clinicopathological, molecular, and survival characteristics of patients with metastatic EGFR-mutant lung adenocarcinoma according to RICTOR mutation status. We retrospectively analyzed 235 patients diagnosed with de novo metastatic lung adenocarcinoma between 2018 and 2024 across three tertiary oncology centers. Patients with targetable oncogenic drivers other than EGFR (ALK, ROS1, HER2, KRAS G12C, BRAF V600E, RET, MET) were excluded. Next-generation sequencing (NGS) was performed using a hybrid-capture panel (Illumina TSO500). Clinical features, co-mutations, treatment responses, and overall survival (OS) were compared between RICTOR-mutant and wild-type subgroups within the EGFR-mutant cohort. Survival analyses employed Kaplan–Meier estimates, log-rank tests, and Cox regression modeling. Of the total cohort, 39 patients (17%) had EGFR-mutant tumors, of whom 15 (38%) carried RICTOR mutations. RICTOR-mutant cases were more likely to be former smokers and presented more frequently with bone and pleural metastases compared with wild type. Treatment patterns and RECIST v1.1 response rates did not significantly differ between groups. Median OS was significantly shorter in RICTOR-mutant versus RICTOR-wild patients (8 vs. 14 months, log-rank p < 0.001). In univariate analysis, RICTOR mutations were associated with inferior OS (HR 2.48, 95% CI 1.73–7.95, p = 0.03), and this association remained significant in multivariate analysis (HR 2.34, 95% CI 1.69–6.75, p = 0.021). Exploratory analyses suggested that RICTOR co-mutations with EGFR exon 19 deletions, exon 18 alterations, or exon 20 alterations were associated with poorer survival outcomes. RICTOR mutations were associated with a high-risk subset of EGFR-mutant metastatic lung adenocarcinoma characterized by more aggressive clinical features and worse survival. These findings suggest the need for prospective validation and support the potential integration of RICTOR status into molecular risk stratification frameworks for precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationLung NeoplasmsAdenocarcinoma of LungRapamycin-Insensitive Companion of mTOR ProteinBiomarkers, TumorHumansRetrospective StudiesFemaleMaleErbB ReceptorsAgedPrognosisMiddle AgedAdultAged, 80 and over

Stichwörter der Autor:innen

Co-mutationEGFR mutationLung adenocarcinomaMTORC2PrognosisRICTOR mutation

Substanzen

ErbB ReceptorsRapamycin-Insensitive Companion of mTOR ProteinEGFR protein, humanRICTOR protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Mehmet Akif Inan Education and Research Hospital, Sanliurfa, Türkiye.
  • Department of Internal Medicine, Mugla Sitki Kocman University Faculty of Medicine, Mugla, Türkiye.
  • Department of Medical Pathology, Adnan Menderes University Faculty of Medicine, Aydin, Türkiye.
  • Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla Universitesi Egitim ve Arastirma Hastanesi, Onkoloji Poliklinigi, Mugla, 48000, Türkiye.
  • Department of Medical Oncology, Mugla Sitki Kocman University Faculty of Medicine, Mugla Universitesi Egitim ve Arastirma Hastanesi, Onkoloji Poliklinigi, Mugla, 48000, Türkiye. dr.ozgur.tanriverdi@gmail.com.

Förderung

  • Mugla Sitki KocmanUniversity

Zitieren

APA

Aytac, A., Ozata, B. M., Erdogdu, I. H., Alkan, A., & Tanriverdi, O. (2026). Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. Virchows Archiv, 489(1), 79-90. https://doi.org/10.1007/s00428-026-04559-2

Vancouver

Aytac A, Ozata BM, Erdogdu IH, Alkan A, Tanriverdi O. Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study. Virchows Archiv. 2026;489(1):79-90. doi:10.1007/s00428-026-04559-2

BibTeX
@article{Aytac2026,
  author = {Aytac, Ali and Ozata, Berkay Mehmet and Erdogdu, Ibrahim Halil and Alkan, Ali and Tanriverdi, Ozgur},
  title = {Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study},
  journal = {Virchows Archiv},
  year = {2026},
  volume = {489},
  number = {1},
  pages = {79--90},
  doi = {10.1007/s00428-026-04559-2}
}
Kostenlos starten →